



Results of Annual General Meeting

NEW YORK and SYDNEY, Australia, May 29, 2020 (GLOBE NEWSWIRE) - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, advises that all resolutions put to shareholders at today's Annual General Meeting were carried on a show of hands. In accordance with section 251AA of the Corporations Act, the Company advises that total number of proxy votes exercisable by proxies validly appointed was 20,690,709. The proxies in respect to each of the resolutions are set out below.

RESOLUTION 1: ADOPTION OF REMUNERATION REPORT

For	Against	Discretion	Excluded
14,526,705	-	-	6,164,004

RESOLUTION 2: RE-ELECTION OF DIRECTOR – TAMEYUKI KAWAGUCHI

For	Against	Discretion	Excluded
20,690,709	-	-	-

RESOLUTION 3: RE-ELECTION OF DIRECTOR – MR PETER YAP TING WONG

For	Against	Discretion	Excluded
20,540,709	-	-	150,000

RESOLUTION 4: RE-ELECTION OF DIRECTOR – MR HAI HUANG

For	Against	Discretion	Excluded
20,690,709	-	-	-

RESOLUTION 5: ISSUE OF NEW SHARES TO EMPLOYEES AND SCIENTISTS

For	Against	Discretion	Excluded
20,690,709	-	-	-

RESOLUTION 6: ISSUE OF SHARES TO RELATED PARTY - MR BOQING ZHANG

For	Against	Discretion	Excluded
20,690,709	-	-	-

RESOLUTION 7: ISSUE OF SHARES TO RELATED PARTY – MR HAI HUANG

For	Against	Discretion	Excluded
18,798,943	-	-	1,891,766

RESOLUTION 8: ISSUE OF SHARES TO RELATED PARTY – MR LIBIN GUO

For	Against	Discretion	Excluded
16,568,471	-	-	4,122,238

RESOLUTION 9: ISSUE OF SHARES TO RELATED PARTY – PETER YAP TING WONG

For	Against	Discretion	Excluded
20,540,709	-	-	150,000

RESOLUTION 10: ISSUE OF SHARES TO RELATED PARTY – DR ZHINAN YIN

For	Against	Discretion	Excluded
20,690,709	-	-	-

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

For more information, please contact:

Investor Contact:

Vivian Chen

Impact IR

Phone: 917-449-4918

Email: vivianchen@irimpact.com

Media Contact:

Cathy Loos

Impact IR

Phone: 347-334-4135

Email: cathyloos@irimpact.com